Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
PR for AFTERHOURS and TUESDAY 10/31
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by Superbee383: [QB] NEOP - .32 Neoprobe 3rd Quarter 2006 Earnings Conference Call Invitation 10/30/2006 Conference Call Scheduled for 10:00 a.m., Friday, November 3, 2006 DUBLIN, Ohio, Oct 30, 2006 (BUSINESS WIRE) -- Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced it would report its financial results for the third quarter of 2006 on Thursday, November 2, 2006 after the close of the financial markets. The announcement will be followed by a conference call scheduled for the next morning, Friday, November 3, 2006, with the investment community at 10:00 AM EST. Neoprobe's President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the company's results for the third quarter of 2006 during the conference call scheduled for 10:00 AM EST, Friday, November 3, 2006. The conference call can be accessed as follows: Conference Call Information--------------------------------------------------------------------- - TO PARTICIPATE LIVE:----------------------------------------------------------------------Date: Nov. 3, 2006Time: 10:00 AM ESTToll-free (U.S.) Dial in # : 877-407-8033International Dial in # : 201-689-8033-------------------------------------------------------------------- -- TO LISTEN TO A REPLAY:----------------------------------------------------------------------Ava ilable until: Nov. 10, 2006Toll-free (U.S.) Dial in # : 877-660-6853International Dial in # : 201-612-7415Replay passcodes (both required for playback): Account # : 286 Conference ID # : 219164---------------------------------------------------------------------- About Neoprobe Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix(R) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek(TM) and RIGScan(R) CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. [URL=http://www.neoprobe.com]www.neoprobe.com[/URL] SOURCE: Neoprobe Corporation Neoprobe Corporation Brent Larson, 614-793-7500 Vice President/CFO or The Trout Group Tim Ryan, 212-477-9007 Copyright Business Wire 2006 [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2